Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEIPP24 Vaccine in Advanced NSCLC
NCT05898763Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TEIPP24 in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Erasmus MC. Primary endpoints: Incidence rate of serious adverse drug reactions at Week 8, Tolerability of adverse drug reactions at Week 8 and 1 more. Started Sep 2021; status: completed.
02
Drugs
TEIPP24
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05898763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898763.